Teva Furnishes 2025 Full Year and Fourth Quarter Financial Results
Summary
Teva Pharmaceutical Industries Ltd. (Teva) furnished its financial results for the period ended December 31, 2025, via a press release (Ex. 99.1) on January 28, 2026. The company reported 2025 revenues of $17.3 billion, a 4% increase year-over-year in U.S. dollars. Key innovative brands significantly contributed to growth, with 2025 revenues surpassing $3 billion, up 35% year-over-year in local currency. - AUSTEDO® global revenues reached $2.26 billion, growing 34% YoY in LC. - AJOVY® global revenues were $673 million, up 30% YoY in LC. - UZEDY® revenues were $191 million, up 63% YoY in LC. - Q4 2025 marked the first quarter where these key brands collectively delivered ~$1 billion in revenues.
Why It Matters
The reported 4% year-over-year revenue growth to $17.3 billion and the strong performance of innovative brands, which collectively surpassed $3 billion in 2025 and reached ~$1 billion in Q4 2025 (via Ex. 99.1), signal consistent execution of Teva's "Pivot to Growth Strategy" and potential for continued value creation. This indicates positive momentum for investors.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how TEVA traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View TEVA Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000818686
- Filing Date
- Wednesday, January 28, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive